Biotech Values

[DewDiligence]

MNTA 2012-2014 News Flow

[Modified entry for FoB program.]


Lovenox

• 24-Jan-2012: Amphastar’s appeal of Lovenox preliminary injunction at the Court of Appeals for the Federal Circuit (Washington DC). Pleadings are due on 1/9/12.

• 25-Jan-2012: NVS reports 4Q12 sales of generic Lovenox. This will be the first quarterly number that shows the effect of Sanofi’s authorized generic.

• 4-Feb-2013: Start of NVS/MNTA’s patent-infringement lawsuit against Teva. (The trial date could be accelerated if this case were consolidated with MNTA’s suit against Amphastar.)


Copaxone

• Early 2012: Court ruling on Copaxone patent trial.

• Timing uncertain: FDA action on Copaxone ANDA.


Other programs

• 1Q12: IND filing for M402, MNTA’s proprietary heparin-based cancer drug, followed by the start of a phase-1 trial.

• Timing uncertain (probably late 2013 or 2014): Announcement of the identities of one or both of the first two FoB’s in MNTA’s partnership with BAX.